Erythropoietin Falls Short of Neuroprotection in Optic Neuritis



A higher rate of conversion to multiple sclerosis in the placebo group offered a glimmer of hope for treatment in TONE, a phase 3 randomized trial, but caveats loom large.
Medscape Medical News

Source link

Comments are closed, but trackbacks and pingbacks are open.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy